Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.66 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.66 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015339 | 0.87 | ALDH1A1 (0.82) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL17482143 | 0.87 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL10721260 | 0.87 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL2415016 | 0.82 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL7819749 | 0.82 | ALDH1A1 (0.82) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL12329596 | 0.81 | ALDH1A1 (0.72) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL10285828 | 0.81 | ALDH1A1 (0.72) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL29805021 | 0.81 | CYP3A4 (0.68) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL1193184 | 0.81 | ALDH1A1 (0.72) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL9173191 | 0.81 | ALDH1A1 (0.72) | ALDH1A1CYP3A4TSHRTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311873-B | Method for preparing 2, 6-dichloro-4-trifluoromethylaniline with 99% content | LIANYUNGANG AVILIVE CHEMICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | claimed |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | DOW AGROSCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3700340-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | Dow Agrosciences LLC (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-107311873-B | Method for preparing 2, 6-dichloro-4-trifluoromethylaniline with 99% content | LIANYUNGANG AVILIVE CHEMICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | disclosed |
| CN-107311873-B | Method for preparing 2, 6-dichloro-4-trifluoromethylaniline with 99% content | LIANYUNGANG AVILIVE CHEMICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3428148-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3088384-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2002-01-24 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
| CN-1319100-A | Isoquinoline derivatives having angiogenesis inhibitory activity | NOVARTIS AG (CH) | 2001-10-24 | — | — | CN | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | disclosed |
| US-4876376-A | Process for the halogenation, nitration and fluorination of aromatic derivatives | RHONE-POULENC SPECIALISTES CHIMIQUES (FR) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | VEGFA, CCNY, PGF | ALDH1A1 1995/4885CYP3A4 1517/4885TSHR 2127/4885 |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | PDXK, DPYD, DDT | ALDH1A1 123/4885CYP3A4 239/4885TSHR 1867/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | ALDH1A1 2909/4885CYP3A4 3705/4885TSHR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.